New drug could help lung transplant patients fight rejection
NCT ID NCT06990711
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a drug called siltuximab in 30 lung transplant patients who are experiencing antibody-mediated rejection, a serious condition that often leads to transplant failure. The drug is added to standard rejection treatment to see if it is safe and tolerable. The goal is to find the best dose with the fewest side effects for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Siltuximab (a drug that blocks interleukin-6, given by IV)
- What this could lead to
- If it works, this could point toward a safer way to treat rejection after lung transplant, potentially improving survival.
- What could go wrong
- This is a very early Phase 1 trial with only 30 people, focused on safety, not effectiveness. The drug may cause side effects or not work better than current treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY MEDIATED REJECTION OF LUNG TRANSPLANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Utah
RECRUITINGSaint Lake City, Utah, 84112, United States
-
Washington University School, of Medicine, Barnes-Jewish Hospital
RECRUITINGSt Louis, Missouri, 63110, United States